1-5 of 5
Heidi Savage
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subtype specific differences in genetic alterations and drug response in breast cancer cell lines

Carol O'Brien, Heidi Savage, Jill Spoerke, Xiaolan Hu, Guy Cavet, Lukas Amler, Mark Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B6.
Published: 15 August 2014
View article titled, Subtype specific differences in genetic alterations and drug response in breast cancer cell lines
Journal Articles

Trastuzamab antibody drug conjugates demonstrate robust in vitro antitumor activity in HER2 amplified breast cancer cell lines

Sankar Mohan, Carol O'Brien, Heidi Savage, Gail Phillips, Howard Stern, Mark Lackner, Ajay Pandita
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): B19.
https://doi.org/10.1158/DIAG-10-B19
Published: 15 August 2014
View article titled, Trastuzamab antibody drug conjugates demonstrate robust <em>in vitro</em> antitumor activity in HER2 amplified breast cancer cell lines
Journal Articles

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Jie Lin, Deepak Sampath, Michelle A. Nannini, Brian B. Lee, Michael Degtyarev, Jason Oeh, Heidi Savage, Zhengyu Guan, Rebecca Hong, Robert Kassees, Leslie B. Lee, Tyler Risom, Stefan Gross, Bianca M. Liederer, Hartmut Koeppen, Nicholas J. Skelton, Jeffrey J. Wallin, Marcia Belvin, Elizabeth Punnoose, Lori S. Friedman, Kui Lin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1760–1772.
https://doi.org/10.1158/1078-0432.CCR-12-3072
Published: 02 April 2013
View article titled, Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Open the PDF for Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O'Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3670–3683.
https://doi.org/10.1158/1078-0432.CCR-09-2828
Published: 14 July 2010
View article titled, Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models in another window
Includes: Supplementary data
Journal Articles

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O'Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (14): 4649–4664.
https://doi.org/10.1158/1078-0432.CCR-09-0317
Published: 15 July 2009
View article titled, <em>In vivo</em> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Open the PDF for <em>In vivo</em> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models in another window
Includes: Supplementary data